U.S. Personal Products Stock News

Why Amphenol’s latest quarter is drawing fresh investor attention Amphenol (APH) is back in focus after its latest quarter, with revenue and earnings coming in above both company guidance and external expectations, supported by expanded capacity and strong demand in defense, commercial aerospace, and data communications. See our latest analysis for Amphenol. Even after the post earnings jump mentioned earlier, the share price has recently cooled, with a 14.21% 1 month share price decline and...

Oklo (NYSE:OKLO) and Centrus Energy announced plans to explore a joint venture to integrate advanced nuclear fuel cycle services. The proposed venture would create a centralized deconversion hub and fuel cycle infrastructure for HALEU at Centrus's Piketon, Ohio site. The partnership targets a more coordinated domestic supply chain for advanced nuclear fuel and reactor deployment in the U.S. Oklo, trading at $53.97, sits at the center of growing attention around advanced nuclear...

In March 2026, CNOOC awarded SLB OneSubsea a multi-well, integrated subsea engineering and production contract for 20 wells at the deepwater Kaiping 18-1 field in the South China Sea, covering standardized subsea systems, installation, and commissioning support. An interesting angle is SLB OneSubsea’s simplified, standardized subsea architecture and in-country manufacturing push, which aims to cut complexity, compress installation timelines, and support future field expansions for...

In March 2026, Arcutis Biotherapeutics reported that Pediatric Dermatology published long-term Phase 3 extension data showing once-daily ZORYVE 0.05% cream remained safe, well-tolerated, and increasingly effective over 56 weeks in children aged 2 to 5 with mild-to-moderate atopic dermatitis, supporting its October 2025 FDA approval. The findings highlight durable disease control and low local irritation in a young pediatric group that often has limited non-steroidal, long-term treatment...

FDA grants premarket approval to LivaNova's aura6000 System for adult patients with moderate to severe Obstructive Sleep Apnea who do not benefit from standard therapies. The system uses proximal hypoglossal nerve stimulation and is supported by clinical trial data showing meaningful outcomes, including in harder to treat patient groups. LivaNova (NasdaqGS:LIVN) also discloses work on a next generation, MRI compatible version of the aura6000 with additional features. LivaNova, listed on...

Event context and recent share performance Honeywell International (HON) shares recently closed at US$221.50, with a return of about 13.1% year to date and 14.3% over the past year, while the past month shows an 8.1% decline. See our latest analysis for Honeywell International. For Honeywell, the recent 8.1% 1 month share price decline comes after an 11.2% 3 month share price return and a 14.3% 1 year total shareholder return, so shorter term momentum is fading against a stronger longer term...

Why Sportradar’s latest earnings and deal activity matter for investors Sportradar Group (SRAD) recently reported 2025 earnings, with revenue up 17% to €1,290 million, supported by US growth and a 109% customer net retention rate. The company also closed the IMG ARENA acquisition. The company extended its exclusive data partnership with MLB for 8 years and added new rights with FIFA and the German DFB Cup, expanding coverage to more than 1 million sporting events each year. See our latest...

RCI Hospitality Holdings (RICK) FY 2025 earnings at a glance RCI Hospitality Holdings (RICK) has just posted its FY 2025 numbers with Q4 revenue of US$70.9 million and a basic EPS loss of US$0.63, set against trailing 12 month EPS of US$1.23 on revenue of US$279.4 million and earnings growth of 259.1% for the period. Over recent quarters, revenue has moved from US$73.2 million in Q4 2024 to US$71.5 million in Q1 2025, US$65.9 million in Q2, US$71.1 million in Q3 and US$70.9 million in Q4,...

If you are wondering whether Northern Oil and Gas at around US$28.84 is offering fair value or a potential mismatch between price and underlying worth, you are not alone. The stock has recent returns of 4.8% over 7 days, 5.4% over 30 days, 31.0% year to date and 2.4% over 1 year, which naturally raises questions about how much is already reflected in the price. Recent coverage has focused on Northern Oil and Gas in the context of its role within the broader energy sector and its position as...

Regulatory milestone and why it matters for TMC the metals (NasdaqGS:TMC) TMC the metals (NasdaqGS:TMC) is back in focus after the National Oceanic and Atmospheric Administration found its consolidated application for Clarion Clipperton Zone exploration and commercial recovery to be in substantial compliance with U.S. deep seabed regulations. See our latest analysis for TMC the metals. The regulatory progress arrives after a sharp reset in the share price, with a 36.25% 90 day share price...

In March 2026, Soleno Therapeutics updated its corporate bylaws, continued outreach with a CEO presentation at the Longwood Healthcare Leaders conference, and faced an investor class action lawsuit alleging inadequate disclosure of safety concerns around its Prader‑Willi syndrome therapy DCCR/Vykat XR. This combination of governance changes, legal scrutiny and discussion of a slower Vykat XR launch puts renewed focus on how safety perceptions and patient adoption may shape Soleno’s...

Caterpillar (NYSE:CAT) is supplying natural gas generators to power the Monarch Compute Campus in West Virginia, one of the world's largest planned AI data center sites. The facility, developed by Nscale and Microsoft, is planned to deliver over 1.35GW of AI compute capacity and is designed to scale to 8GW. Caterpillar's G3500 generators are contracted to provide independent on site power for this multi gigawatt AI data center build. The company also has a separate global framework agreement...

Why Penske Automotive Group (PAG) Is On Investors’ Radar Today Penske Automotive Group (PAG) has come into focus after a stretch of weaker recent share performance, with the stock showing negative returns over the past week, month, past 3 months and year to date. That softer run contrasts with the company’s longer multi year track record. The 3 year and 5 year total returns remain positive, prompting some investors to reassess how current pricing lines up with the underlying business. See our...

Relay Therapeutics (RLAY) is back in focus after presenting new Phase 1/2 ReDiscover data for zovegalisib plus fulvestrant, where a 400 mg twice-daily fed dose showed efficacy and safety in line with earlier higher-dose findings. See our latest analysis for Relay Therapeutics. The updated zovegalisib data arrives after a powerful swing in sentiment, with Relay Therapeutics’ 1 year total shareholder return of 223.86% contrasting with a 5 year total shareholder return loss of 71.07%. Its 30 day...

Alcoa (NYSE:AA) is seeing stronger interest from aluminum buyers following supply chain disruption linked to the closure of the Strait of Hormuz. Customers are seeking alternative suppliers outside the Gulf region, and Alcoa reports a surge in inquiries for its aluminum products. The company is benefiting from higher aluminum prices and premiums in the United States as buyers adjust sourcing plans. For investors watching industrial metals, this shift puts Alcoa, a major upstream aluminum...

Microvast Holdings (MVST) is back in focus after reaffirming and expanding its long running battery partnership with Iveco Group in Europe, alongside releasing 2025 results, 2026 guidance, and an auditor warning on going concern risks. See our latest analysis for Microvast Holdings. Despite a series of material updates including the expanded Iveco partnership, 2025 results, 2026 guidance and the going concern warning, Microvast’s recent share price performance has been weak. The 30 day share...

If you are wondering whether Viridian Therapeutics at around US$26.98 is offering good value or asking too much, you are in the right place. The stock has recently seen mixed returns, with a 7 day move of 5.9% decline and a 30 day return of 4.0% decline, while still sitting on a 76.8% gain over the past year and 12.1% decline year to date. Recent news coverage has focused on Viridian Therapeutics as a biotech name that continues to attract attention from investors watching the sector. This...

Coherent (COHR) is back in focus after high profile product showcases at OFC 2026 and an expanded multiyear partnership with Nvidia, including a sizeable investment and a long term AI photonics supply commitment. See our latest analysis for Coherent. The recent Nvidia partnership and OFC 2026 showcases come after a powerful run, with a 30.52% year to date share price return and a very large 1 year total shareholder return. This hints that investors see rising potential in Coherent’s AI...

If you are wondering whether Abbott Laboratories at around US$105 per share looks like an opportunity or a value trap, the starting point is understanding what the current price actually reflects. The stock has seen a 2.4% decline over the past week, a 6.9% decline over the last month, and a 15.1% decline year to date, with a 15.0% decline over the past year and a 14.1% gain over three years. These moves are set against a backdrop of ongoing attention on large healthcare names, with...

In March 2026, UGG, a division of Deckers Brands, launched its Spring 2026 Golden Collection, turning its iconic cold-weather classics into warm-weather sandals and clogs available through UGG.com, UGG stores, and select wholesale partners. The collection’s emphasis on year-round use of the UGG aesthetic, recycled materials, and contrasting textures highlights the brand’s push to extend its signature comfort beyond winter and deepen engagement with both existing and new customers. Next,...

What Argan’s Recent Share Move Tells You Argan (AGX) has drawn fresh attention after a strong price move over the past 3 months, with the stock showing a 45.54% total return and a 14.42% gain over the past month. See our latest analysis for Argan. That recent 30 day share price return of 14.42% builds on a strong 90 day run of 45.54%, while the 1 year total shareholder return of 296% and very large 3 year and 5 year total shareholder returns suggest momentum has been firmly positive for some...

AOP Health’s decision to run its rare disease and intensive care operations on Veeva Systems (VEEV) cloud platforms highlights how deeply Veeva’s software can be embedded across clinical, regulatory, safety, and commercial workflows. See our latest analysis for Veeva Systems. Even with news like the AOP Health rollout highlighting real world use of its platforms, Veeva’s share price tells a mixed story. A 7 day share price return of 2.9% is set against a 1 year total shareholder return...

Biogen recently saw a federal securities class action certified for investors who acquired its shares between June 8, 2021 and July 12, 2021, while also highlighting investigational therapies such as litifilimab for cutaneous lupus erythematosus and salanersen for spinal muscular atrophy at major medical meetings. Together, the class action certification and progress in autoimmune and neuromuscular drug pipelines underscore how Biogen’s legal exposure and innovation efforts are evolving in...

In recent weeks, oil prices have climbed sharply following the Iran conflict, pushing Brent crude above US$100 per barrel and refocusing attention on efficient US producers such as EOG Resources. The key angle for investors is how EOG’s reputation for low-cost, high-productivity wells may allow it to convert higher prices into additional excess cash to reinvest and return to shareholders. We’ll now examine how this period of elevated oil prices could influence EOG Resources’ existing...